The interest in the synthesis of metallic complexes of different drugs to make them more efficient in biological environment of the human body is seen for the last few decades. Wide range of metal complexes are already used in clinical practice which encourages additional research for innovating new metal based drugs, such as metal-mediated antibiotics, antiparasitic, antiviral, antibacterial, and anticancer compounds. Tuberculosis has been known as one of the most disastrous disease putting burden on health system worldwide. Though the therapeutic agents to combat the disease are well practiced, emergence of multi drug resistant strains makes the treatment strategies more difficult. The following work aims to synthesize copper, ferrous, ferric, cobalt and manganese complexes of renowned anti tuberculosis drug, pyrazinamide (PZ). These compounds were tested for anti-tuberculosis using five multidrug resistant strain of Mycobacterium tuberculosis. For this purpose BACTEC MGIT 960 system was used. The drug PZ was also screened with the synthesized complexes. The two complexes of cobalt and manganese proved potent among all of the compounds tested.

Novel 4-(diphenylphosphoryl)-1-phenylbutane-1,3-dione was synthesized by the reaction of diketone enamine with diphenylchloro phosphine followed by oxidation and hydrolysis of the enamine phosphine formed. Tautomeric transformation of the diketone moiety of phosphine oxide was investigated by ¹H NMR. Three out of five possible tautomers were observed in the 4-(diphenylphosphoryl)-1-phenylbutane-1,3-dione solution. The major tautomer was the form with a diketone fragment.